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Abstract 
Background: To determine the frequency and 
specificities of red blood cells -antibodies in multi-
transfused cancer patients.  
Methods: From total of 150 patients, 24 patients 
were diagnosed with haematological and 126 with 
non-haematological malignancies. Their medical 
records were reviewed and sorted by diagnosis, 
treatment medications, and past transfusion and/or 
treatment history. Only those patients were enrolled 
who had received at least five transfusions during 
the treatment. Antibody screening was performed by 
using commercial three-cell panel according to 
standardized methods. Allo-antibody was identified 
by using 11 cells panel.  
Results: Total patients with malignant disorders 
included 44 males and 106 females. Nine patients 
(6%) with non haematological malignancies 
possessed RBC allo-antibodies. The distribution of 
different allo-antibodies in positive patients was 
anti-D in 3 patients, anti-E in 2 patients while anti- 
Fya, anti Fyb, anti-Jka and anti-K were positive for 1 
patient in each. The presence of allo-antibodies was 
statistically significant in patients with higher 
number of transfusions (p-value 0.001).  
Conclusion: Allo-antibodies against Rh system 
were most frequent. Incidence of RBCs allo-
immunization increases with the number of 
transfusion and the number  of donor exposures to 
the recipient. 
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Introduction 
   Cancer patients commonly develop significant 
anaemia of chronic disease (ACD).Anaemia in patients 
with malignancy  might be due to the disease process 
itself or due to myelo-suppressive therapy. 
Transfusions are therefore often offered to patients 
with all types of cancer as symptomatic palliation 
when they develop severe anaemia.1,2 The requirement 
of transfusion with blood or its components may vary 
from patient to patient. Some may need numerous 
units of different types of blood components before 
their bone marrow recovers while others only require 
fairly small numbers of transfusions for the surgical 
removal of tumor burden.3 
     Red blood cell (RBC) allo-immunization is one of 
the important detrimental effect that occur with 
repeated transfusions of allogeneic blood.4  It is known 
that allo-immunization to red cell (RBC) antigens is the 
outcome of genetic discrepancy that is present 
between donor and recipient blood cells. RBC allo-
antibodies develop in more than 30 percent of patients 
receiving multiple transfusions and can prove to be a 
major problem in the case of long-term transfusion 
therapy.5 Frequency of the transfusions may also 
influence allo-immunization.6 Other risk factors for 
RBC alloimmunization include female sex, a history of 
pregnancy, underlying disease and racial differences 
between recipients and blood donors .4 
     Compatibility testing is routinely carried out with 
respect to major blood group antigens i.e. ABO and Rh 
antigens. There is always a high probability that the 
donor might have minor blood groups antigens which 
may not be present in the recipient blood which will 
lead to in RBCs alloimmunization.7 Majority of the 
antigens present on the erythrocytes usually do not 
give rise to antibodies formation even when injected 
into patients lacking the same antigen. This rate of 
immunization ranges from 70% for Rh ‘D’ antigen to 
as low as 0.5% for the Duffy antigens.4  
   Some of the antibodies are clinically insignificant but 
other may cause severe haemolytic transfusion 
reactions.  Reaction to  these allo-antigens may also 
vary   from person to person.8 Clinically  significant 
allo-immunization develops with the Rhesus, Kell, 
Duffy and Kidd system.7  If antibody against red cell 
antigen develops this will  increase the need of 
transfusion and can complicate transfusion therapy 
further.8 Therefore it has been advocated that 
transfusion-dependent  patient should be given blood 
matched for antigens other than ABO and D (e.g., C, E, 
c, and K) to prevent allo-immunization. However, a 
cost-effective consideration as well as the question  
whether this would truly add to the patient’s safety 
still makes it a matter of debate.5 
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     In Pakistan, not only the data regarding allo-
immunization in multiple transfused cancer patient is 
scarce but elaborate data on various blood group 
systems (other than ABO and Rh ‘e.g., Kell, Duffy, 
Kidd, MNS, Lewis, etc.) is also lacking. Allo-antibodies 
can lead to serious clinical consequences and problems 
like obtaining properly and timely matched blood for 
these patients.Identifying such high-risk group will be 
a possible target for extended matching.9   
 
Patients and Methods 
     In this cross-sectional study patients with different 
types of malignant disorders, from August 2011 to 
November2011, were enrolled. Patients were 
randomly selected by examining their records of 
transfusions and immuno-hematologic studies  
obtained from the blood bank of INMOL Hospital, 
Lahore, Pakistan. The data included all tests 
performed for each patient during their previous 
admissions to the hospital. Information regarding age, 
sex, type of malignancy, treatment record, transfusion) 
history (date, quantity, and type of blood component 
),total number and time period from last transfusion 
given were noted. Patients who had received more 
than five transfusions were included in study. Patients 
having a known antibodies against RBCs antigen were 
excluded.8  Blood was collected  from each patient in 
vaccutainer without additives. Samples were allowed 
to clot before centrifugation, at 2000g for 10 minutes to 
obtain serum. Serum were separated in aliquot and  
tested for the presence of allo-antibodies by using 
commercial three cells panel. The technique for 
antibody screening and detection involved the use of 
100 μL of serum and 50 μL 5% RBCs in a saline, 
albumin, and antiglobulin tube test. In case of positive 
screening commercially prepared, eleven cells panel 
(DiaMed, DiaPanels Test cell panels) were used for 
antibody identification. Interpretation of panel results 
was carried out using ruling out and matching 
patterns.5 
 
Results 
     A total number of 150 patients with malignant 
disorders and who had received multiple transfusions 
were randomly selected. These patients were divided 
into two groups: Group I comprised of patients having 
haematological malignancies and group-II included 
patients with non haematological malignancies(Table-
1).There were 24 patients in group I (16%), they were 
diagnosed  cases of  non Hodgkin’s lymphoma, acute 
lymphoblastic leukaemia, Hodgkin’s disease, multiple 
myeloma, acute myeloid leukaemia and chronic 
lymphocytic leukaemia (Table 2). All of them received 
chemotherapy while only 3 patients were given 
radiotherapy in addition to chemotherapy. None 
developed alloantibody against RBCS antigen. 
 
Table-1: Demographic Data of Patients 
Variables Mean+SD of Total Patients 
Mean+SD of 
Haematological 
Malignancies 
Patients 
Mean+SD of 
Non-
Hematological 
 Malignancies 
Patients 
 
p value 
Number of 
patients 
150 
 
24  (16%) 126 (84%)  
Age of Patient 42.90+ 12.10 44.17 + 15.74 42.67+ 11.35 0.58 
Sex of patients 
M/F 
44/106 18/6 28/98 0.76 
 
Duration of 
Disease (Months) 
19.43 + 22.58 
 
15.58  + 17.28 20.07 + 23.45 0.364 
Number of 
transfusion given 
9.73 + 4.0 
 
10.79 + 6.0 9.48 + 3.53 0.00 
 
Table 2: Basic features of Alloimmunized 
and non immunized multiple 
transfused cancer patients 
  Alloimmunized Non immunized 
p-value 
Number of patients 
 
 
9 (6%) 
 
 
141 (94%)  
 
 
Mean age in years 48.8 42.52 0.12 
Sex ratio (F/M) 6/3 100/41 0.97 
Mean transfusion  
Episodes 
19.11+3.48 9.94 +3.33 0.00 
Disease group Solid  
Malignancy 
Solid and  
haematological 
Malignancies 
0.17 
 
Table 3: Frequency of different RBCs 
alloantibodies in multiple transfused cancer 
patients 
Antibodies Detected  No of Patients Percentage 
 Anti E 2 22.2% 
 Anti- D 3 33.3% 
 Anti-K 1 11.11% 
 Anti-Jk a 1 11.11% 
Anti-Fy a 1 11.11% 
Anti Fy b 1 11.11% 
 
        Group II included 126 (84%) patients. They were 
diagnosed  cases of carcinoma of breast, lung, ovary, 
colon, rectum , prostate, gall bladder, pancreas, brain, 
kidney, larynx, oesophagus, nasopharynx, cervix and 
bones. Few cases of adeno-squamous carcinoma, germ  
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Table 4: Red cells alloimunization in repeatedly 
transfused cancer patients-Diseases   and 
transfusions 
Entity No of 
patients 
Disease duration 
(months;mean) 
No of 
transfusions 
(Mean) 
Haematological Malignancies 
Non Hodgkins 
Lymphoma 
11 13 0 
Acute 
Lymphoblastic 
Leukaemia  
5 8 14 
Multiple 
Myeloma 
2 36 8 
Hodgkins 
Disease 
3 28 7 
Chronic 
Lymphocytic 
Leukaemia 
1 12 7 
Acute Myeloid 
Leukaemia 
2 5 8 
Non-Haematological Malignancies 
Ovary 8 12 9 
Breast 69 14 8 
Colon 6 15 13 
Rectum 4 5 8 
Lung 9 7 9 
Prostate 5 17 10 
 
cells tumour, seminoma, Ewing’s sarcoma and 
leiomyosarcoma were also included in this group 
(Table 2). Red cell allo-antibodies were positive in 9 
patients in this group. In group II out of 9 patients who 
were positive for RBC antibodies, three were 
diagnosed cases of carcinoma of breast, two of 
carcinoma of pancreas and one patient each was of 
carcinoma of cervix, kidney, colon and Ewing’s 
sarcoma. Six of these patients were on chemotherapy 
and three were using combined therapy 
(chemotherapy and radiotherapy). 
     In a total of 150 cases only nine patients (6%) were 
found to be allo-immunized to RBC and all of them 
belonged to group II (non haematological malignancy) 
(Table 2). The positivity of allo-antibodies was 5.6% in 
females and 6.8% in  males (p=0.97) (Table-3). The 
number of transfusion episodes were significantly 
associated with the rate of alloimmunization (p value = 
0.001). The distribution of different allo-antibodies was 
that anti-D was detected in 3 patients, anti-E in 2, 
while anti- Fya, anti Fyb, anti-Jka and anti-K were 
detected in one patient each (Table 4). 
 
Discussion 
     The prevalence of anaemia in cancer patients at 
different stages of disease and treatment is around 
40%.(10).Transfusions of red cells are the most 
common treatment for cancer related anaemia. 
Clinically, significant RBC allo-antibodies can pose 
major problems in the case of long term transfusion 
therapy.5   Studies in patients observing the incidence 
of RBCs allo-immunization ranges between 1%- 6% in 
occasionally transfused and up to 30% in poly-
transfused patients.9 In our study the overall 
prevalence of allo-antibodies in cancer patients was 
observed to be 6%.Our findings are comparable to a 
study by Schonewille  on patients with malignant 
disorders who described the overall immunization rate 
about 9%. Antibody formation in patients with 
malignancies is comparable to that in other diseases 
requiring multiple blood transfusions.5 In other studies 
allo-immunization to RBCs was positive in 
7.4%patients in Iran 22% in Saudi Arabia 6.1% in 
Uganda and 9.2% in our local population in patients 
who received multiple transfusions with different 
diseases.4,6,7,12  
     Inflammation in patients can also be  a leading 
factor for alloimmunization and further studies are 
required in this regard which may contribute in a high 
standard of such patients care.  Trivial variation in 
frequency of allo-antibodies to RBCs may be due to 
multiple reasons. Few factors that might be 
responsible for the disparity in results include patient 
population being studied, the transfusion protocols 
being followed, sensitivity of the test methods, and the 
proficiency of the laboratory employees.  Slightly 
lower prevalence in our patients may be explained by 
previous reports showing that cancer patients have 
lower rates of allo-immunization to RBC antigens 
because they are immune-suppressed and may not 
manifest any evidence of prior allo-immunization.5,13 
Study of the transfusion records unveiled that the risk 
of RBCs allo-immunization increases with the number 
of transfusion and the number of donor exposures.9,12 
This was also the case in allo-immunized patients in 
our study. Average number of transfusions received 
was 19.11 in allo-immunized patients as compared to 
non-immunized patients in whom average number of 
transfusion episode was 9.94. A positive and 
statistically significant relation7 was found between 
the presence of allo-antibodies and number of 
transfusions . Similar results were found in a study 
conducted in Iran, showing higher red cells allo-
immunization in patients who received more units of 
blood.6 Cumulative incidence of allo-immunization 
increases with number of units of red blood cells being 
transfused.14 There was an interesting finding in our 
study that none of the patients with haemotological 
malignancy developed antibodies against RBCs. It has 
been reported previously that lymphoproliferative 
diseases and leukaemia have lower risk of allo-
immunization attributed to lymphocyte dysfunction 
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leading to lack of immune response.9  While several 
studies indicate that lymphocytic leukemia may be 
characterized by a lack of immunologic response, a 
study conducted in Netherlands failed to demonstrate 
a significant difference between CLL patients and 
patients from other disease groups.5  It is however 
difficult  to make conclusions on alloimmunization 
incidence in the patients with hematological  diseases 
in our study due to  less number of the patients in this 
group .Further studies are required with a larger 
sample size  to elucidate the phenomenon of low risk 
of alloimmunisation in such patients.2  
     In our study the distribution of different allo-
antibodies in positive patients was anti-D in 3 patients, 
anti-E in 2  patients, anti- Fya, anti Fyb, anti-Jka, and 
anti-K one  patient each. The antibodies found in this 
study were from the Rh, Duffy, Kidd and KELL 
groups. Out of nine positive patients found in our 
study, 5 (55 %) patients with malignant disorders were 
positive for alloantibodies against Rh system. 
Comparable results have been reported in another 
study conducted at Rawalpindi on our local 
population demonstrating that the red cell allo-
antibodies detected in multi transfused patients 
belonged mainly to Rh system.15  A study conducted in 
Karachi Pakistan also revealed that red cell allo-
antibodies were mainly from Rhesus and Kell system.7 
 The most suitable explanation for this could be  that in 
developing country like ours proper management is 
not  readily available in cases following potential 
sensitization events such as abortions and pregnancies 
in Rh negative female and majority of our study 
population was women. Moreover genetic factors and 
ethnicities effect  the development of alloantibodies. 
Which might have influenced the higher incidence of 
developing anti Rh antibodies observed in this current 
study. The RBC antigens and allo-antibodies differ 
significantly among human populations and ethnic 
groups was also studied in Malaysia suggesting that 
anti-E and Lewis allo-antibodies are the most common 
allo-antibodies among populations there. (16). Our 
study should however stimulate more work in our 
community to highlight the blood groups that have the 
potential for alloantibody formation. 
 
Conclusion 
1. RBC allo-antibodies may cause difficulty in 
obtaining compatible, antigen-negative RBCs blood in 
multi-transfused patients. 
2. Multiple transfused patients should be screened 
against red cell alloantibodies, as the presence of these 
antibodies can lead to an inadequate haemoglobin 
level escalation as well as to transfusion reactions 
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